Pump Supplies denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for pump supplies are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Issues an Experimental Denial for Pump Supplies

Blue Cross Blue Shield occasionally denies insulin pump supplies — particularly supplies associated with advanced pump systems such as automated insulin delivery (AID) or hybrid closed-loop technology — as "experimental or investigational." This denial most often applies to newer pump systems or supply types that BCBS has not yet added to its covered technology list, or to specific sensor or algorithm components where BCBS's internal evidence review has not yet concluded the technology meets its coverage threshold.

These denials are frequently overturned on appeal because insulin pump therapy has a long, well-established evidence base, is supported by major professional societies, and the FDA-clearance status of specific devices is verifiable. If the denial applies to a specific advanced feature rather than pump therapy generally, the appeal can often be narrowed to that feature.

## Your Federal Appeal Rights

• Internal appeal: ACA §2719 and ERISA §503 require BCBS to provide a full written explanation of what specific technology or supply it considers experimental, including the evidence standard it applied. You are entitled to request the clinical review criteria used.
• External review: For "experimental" denials specifically, federal and most state laws guarantee access to independent external review. The external reviewer applies an objective evidence standard — not BCBS's internal policy. File window is typically approximately four months after final internal denial.
• Expedited track: Available if supply interruption poses an immediate clinical risk.

## Documentation to Gather

1. FDA clearance documentation — obtain the FDA 510(k) clearance or PMA approval for the specific pump and supply components at issue. This is publicly available on the FDA device database. 2. Prescriber letter — your physician should affirm that the prescribed system is FDA-cleared, has an established evidence base, and is consistent with current American Diabetes Association (ADA) and/or AACE standards of care. 3. Clinical necessity for the specific technology — if an advanced pump system was prescribed over a conventional pump, document the specific clinical reason (e.g., hypoglycemia unawareness, glycemic variability) that makes the more advanced system medically necessary. 4. ADA/AACE guideline reference — cite the relevant professional-society guidance supporting use of the prescribed technology in your clinical scenario.

## Criteria-Mapping Structure

| BCBS Experimental Criterion | Your Evidence of Established Status | |---|---| | [Paste BCBS's experimental-technology standard] | [FDA clearance date, ADA/AACE guideline citation, physician statement] |

## Next Step

If BCBS's denial letter does not specify which supply component or technology feature it considers experimental, request that clarification in writing before filing your full appeal. A narrowly scoped appeal targeting the specific issue BCBS identified is more effective than a broad response.